Wegener's granulomatosis. Long-term followup of patients treated with cyclophosphamide.

Arthritis and Rheumatism
M J RezaC M Pearson

Abstract

Ten patients with Wegener's granulomatosis were treated with cyclophosphamide and followed for periods up to 7 years. In all cases cyclophosphamide induced complete remissions. The mean duration of remission (to date) was 38 months. Six patients have been in remission for a mean of 46 months after cyclophosphamide was discontinued; 2 have been disease-free for 7 years. Of the 10 patients treated, only 1 relapsed and she responded to a second course of cyclophosphamide. These results indicate that cyclophosphamide is the drug of choice in Wegener's granulomatosis. The long-term effectiveness of this drug suggests that it may induce permanent remissions in certain patients with Wegener's granulomatosis.

References

Oct 1, 1974·Annals of Internal Medicine·S M WolffD C Dale
Apr 29, 1971·The New England Journal of Medicine·S N Novack, C M Pearson
Aug 2, 1958·British Medical Journal·E W WALTON

❮ Previous
Next ❯

Citations

Aug 2, 1979·The New England Journal of Medicine·A S FauciS M Wolff
Jan 1, 1989·Arthritis and Rheumatism·J D BradleyB P Katz
Jan 1, 1987·Rheumatology International·P BamberyK S Chugh
Feb 1, 1981·Journal of Cutaneous Pathology·T LeC M Lapière
Apr 1, 1995·The Journal of Urology·R PiazzaM Piazza
Jan 7, 1998·Arthritis and Rheumatism·G S Hoffman
Aug 1, 1990·Clinical Otolaryngology and Allied Sciences·G E Murty
Oct 1, 1991·Clinical Otolaryngology and Allied Sciences·G E MurtyD A Savage
Jan 1, 1981·Clinical and Experimental Dialysis and Apheresis·J E Balow
Apr 1, 1988·Arthritis and Rheumatism·T J StillwellL H Weiland
Aug 1, 1983·Hospital Practice·R Bluestone
May 1, 1981·The Annals of Otology, Rhinology, and Laryngology·P Illum, K Thorling
Apr 1, 1993·Australian and New Zealand Journal of Medicine·E RomasJ F Niall
Sep 1, 1992·Journal of Internal Medicine·A A DrososH M Moutsopoulos
Jun 1, 1980·The Journal of Laryngology and Otology·I H Calonius, C K Christensen
Jan 1, 1982·Clinical and Experimental Dermatology·M E Kesseler
Sep 1, 1978·The Annals of Otology, Rhinology & Laryngology. Supplement·S R CohenH Isaacs
Sep 1, 1996·Renal Failure·M E GriffithC D Pusey
Mar 4, 2021·BMJ Case Reports·Jessie Jia TaoChristian Pagnoux
May 1, 1980·Seminars in Arthritis and Rheumatism·P T FanR Bluestone
Aug 1, 1981·Seminars in Arthritis and Rheumatism·S B Cohen, E R Hurd
May 1, 1986·Seminars in Arthritis and Rheumatism·P J Clements, J Davis
Jan 1, 1997·The Medical Clinics of North America·N B Allen, P B Bressler
Jun 1, 1985·Kidney International·J E Balow

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.